Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1385&sort=award_amount
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=award_amount", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1397&sort=award_amount", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1386&sort=award_amount", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=award_amount" }, "data": [ { "type": "Grant", "id": "8099", "attributes": { "award_id": "75N92021C00007-0-9999-1", "title": "RAPID ACCELERATION OF DIAGNOSTICS (RADX) TECH PROGRAM - PROJECT #6658", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-02-02", "end_date": "2022-02-01", "award_amount": 10295000, "principal_investigator": { "id": 23981, "first_name": "DAVID", "last_name": "YOO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1672, "ror": "", "name": "GENBODY INC.", "address": "", "city": "", "state": "", "zip": "", "country": "KOREA REP OF", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1672, "ror": "", "name": "GENBODY INC.", "address": "", "city": "", "state": "", "zip": "", "country": "KOREA REP OF", "approved": true }, "abstract": "A method was developed to detect not only SARS-CoV-2, but also influenza A and Influenza B anigen at the same time in a single lateral flow rapid testing (LFRT) system. The kit is a single device that can detect SARS-CoV-2 antigen and influenza antigen simultaneously. Since Influenza with respiratory illness with symptoms of high fever is similar to COVID-19, there are many difficulties to distinguish it from clinical diagnosis. Influenza can be treated with antiviral drugs such as Tamiflu, and there are also defense measures such as vaccines, so the treatment method is different. We have developed and evaluated an analytical/clinical performance for rapid diagnosis kit of SARS-CoV-2 antigen, obtained approval from the Korean Food and Drug Administration, and diagnostic Kits for influenza A/B antigen have also been licensed and commercialized. This diagnostic kit is basically diagnosed through the naked eye, and a portable equipment (Confiscope G20 has CE but no FCC) can be used for accurate determination which can be applied to control systems using a network.", "keywords": [ "2019-nCoV", "Antigens", "Antiviral Agents", "COVID-19", "COVID-19 detection", "Clinical", "Devices", "Diagnosis", "Diagnostic Reagent Kits", "Equipment", "Eye", "Fever", "Influenza", "Influenza A virus", "Influenza B Virus", "Koreans", "Lateral", "Measures", "Methods", "Oseltamivir", "Performance", "RADx Tech", "SARS-CoV-2 antigen", "Symptoms", "System", "Time", "United States Food and Drug Administration", "Vaccines", "clinical Diagnosis", "portability", "programs", "rapid diagnosis", "rapid testing", "respiratory" ], "approved": true } }, { "type": "Grant", "id": "12023", "attributes": { "award_id": "5UL1TR001873-08", "title": "Clinical and Translational Science Award", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 21618, "first_name": "Audie A", "last_name": "Atienza", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-08-01", "end_date": "2026-05-31", "award_amount": 10299800, "principal_investigator": { "id": 27907, "first_name": "Muredach P", "last_name": "Reilly", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 781, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Contact PD/PI: Reilly, Muredach P OVERALL: PROJECT SUMMARY/ABSTRACT Our mission is to improve the health of our patients and communities both locally and nationally through innovations in clinical and translational research. Our strategic vision is to catalyze all phases of clinical and translational science (T0-T4), synergize with our partners and stakeholders, and integrate activities within our hub and across the national Clinical and Translational Science Award (CTSA) Program. To achieve this vision, we will build on our strong established track-record (e.g., in precision medicine), our plans to tackle important public-health challenges (e.g., COVID-19 pandemic, the opioid crisis) and to address critical barriers (e.g., innovation in use of electronic health records for research, clinical trial designs) as we embrace the CTSA Program priorities designated in PAR-18-940. Our vision is to transform the health and wellbeing of our communities in New York City, the nation and the world. To achieve this, we deploy our programs and resources to develop, demonstrate and disseminate innovations in clinical and translational science across the full translational spectrum. As a comprehensive CTSA, we offer a broad array of support for trainees, scholars and investigators across our entire hub which includes Columbia University, the Columbia University Irving Medical Center, the New York Psychiatric Institute, and New York Presbyterian Hospital. At the same time, we move flexibly and deeply to address critical scientific or institutional opportunities as well as major public health needs and gaps. We achieve success by approaching our goals at multiple levels: a) Ongoing strategic planning including an annual retreat to review operations and identify gaps, needs and opportunities; b) Monthly cross- cutting “Theme” meetings to enable collaborative problem-solving in addressing gaps and opportunities; c) An innovative Evaluation and Continuous Improvement strategy using participatory management to integrate evaluation into program planning and execution; and d) A highly successful, innovative interdisciplinary training and workforce development program built on a foundation of team science. Central to our efforts to improve health and wellbeing at personal, community and national levels is our emphasis on strategic collaboration and dissemination. Thus, we seek to continuously create and refine innovations for an integrated research- and user- friendly translational research environment at our hub by: Harnessing partnerships across our entire hub; Transforming collaborations with our local communities, the campus health system and across New York State; And by accelerating bidirectional dissemination of innovative practices and learnings through collaborations with the CTSA Program network and beyond. Project Summary/Abstract Page 221 Contact PD/PI: Reilly, Muredach P Narrative The Clinical and Translational Science Award (CTSA) allows Columbia University to support novel programs whose goal is to speed the transition from scientific discoveries made in the laboratory toward new therapies. Building on our strong established track-record, we will tackle important challenges and critical barriers to research. We will facilitate the training of scholars from diverse backgrounds underrepresented in translational science who are knowledgeable about and available to focus on translational science later in their careers.", "keywords": [ "Acceleration", "Address", "COVID-19 pandemic", "Clinical Research", "Clinical Sciences", "Clinical Trials Design", "Clinical and Translational Science Awards", "Collaborations", "Communities", "Dental", "Education", "Electronic Health Record", "Environment", "Evaluation", "Evolution", "Faculty", "Foundations", "Friends", "Goals", "Health", "Health Benefit", "Health system", "Healthcare", "Hospitals", "Infrastructure", "Institution", "Interdisciplinary Study", "Laboratories", "Lead", "Leadership", "Learning", "Medical center", "Medicine", "Methods", "Mission", "Modeling", "New York", "New York City", "Patients", "Personal Satisfaction", "Phase", "Physicians", "Presbyterian Church", "Problem Solving", "Process", "Program Development", "Public Health", "Public Health Schools", "Recording of previous events", "Research", "Research Methodology", "Research Personnel", "Resources", "School Nursing", "Schools", "Science", "Speed", "Strategic Planning", "Strategic vision", "Surgeon", "Time", "Training", "Translational Research", "Universities", "Vision", "Workforce Development", "career", "college", "dissemination science", "experience", "flexibility", "implementation science", "improved", "innovation", "meetings", "member", "novel", "novel therapeutics", "operation", "opioid epidemic", "precision medicine", "programs", "success", "synergism", "translational pipeline", "user-friendly" ], "approved": true } }, { "type": "Grant", "id": "15551", "attributes": { "award_id": "75N95024D00006-P00001-759502400001-1", "title": "TO1 - STSS PROGRAM SUPPORT 1.0", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-02-08", "end_date": "2024-05-31", "award_amount": 10367151, "principal_investigator": { "id": 26488, "first_name": "GARY", "last_name": "MAYS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2550, "ror": "", "name": "AXLE INFORMATICS, LLC", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "National COVID-19 Cohort Collaborative (N3C): The National COVID-19 Cohort Collaborative (N3C) sponsors the NIH COVID-19 Data Enclave, one of the largest data enclaves in the world supporting COVID-19 research. N3C is a partnership among the NCATS-supported Clinical and Translational Science Awards (CTSA) Program hubs, with overall stewardship by NCATS. The N3C program consists of thousands of researchers, requiring enterprise level information technology (IT) support as part of a virtual research organization (VRO). This contract is necessary to ensure that NCATS and N3C can continue to provide adequate support for a secure, collaborative, VRO. This contract allows for continued support of the VRO which supports all of the required information technology functions to support an environment of over 4,000 users, including cloud-based productivity tools, a service desk, commercial and open-source deployments of analytical tools for the community to use, and expansion of the data types available for analysis, such as imaging, viral variant genomic sequences, etc. The common need is to share a collaborative cloud environment capable of ingesting billions of data points and performing a variety of complex analyses against multimodal data types, ranging from pathology and radiology data, synthetic data, genomic information, electronic health records (EHRs) and a wide variety of others. All of this must be done while meeting the highest levels of security and privacy, given the sensitivity of some of the data types being collected and the importance of the work being done in the environment. This contract provides support for all of these enterprise IT efforts.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "6429", "attributes": { "award_id": "3UM2AI117870-06S1", "title": "Rho Federal Systems Division, Inc. NIAID DAIT SACCC", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 21604, "first_name": "Leighton A.", "last_name": "Thomas", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-05-08", "end_date": "2023-04-30", "award_amount": 10601507, "principal_investigator": { "id": 21605, "first_name": "Samuel", "last_name": "Arbes", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1465, "ror": "", "name": "RHO FEDERAL SYSTEMS DIVISION, INC.", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 21606, "first_name": "Gloria", "last_name": "David", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1465, "ror": "", "name": "RHO FEDERAL SYSTEMS DIVISION, INC.", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 1465, "ror": "", "name": "RHO FEDERAL SYSTEMS DIVISION, INC.", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT COVID-19, the infectious disease caused by SARS-CoV-2, is rapidly affecting humans around the globe. While initial epidemiological data have focused on cases that resulted in severe respiratory disease seen predominantly in adults, little information regarding the infection burden in children is available. This is complicated by the observation that many virologically confirmed cases in children are asymptomatic (Dong et al, Pediatrics, PMID 32179660). Undocumented, and likely infectious, cases could result in exposure to a far greater proportion of the community than would otherwise occur. Indeed, it has been proposed that undocumented (or silent) infections are the source for almost 80% of documented infections (Li et al, Science, PMID 32179701); thus, it is critical to determine the silent and symptomatic infection rate in children. The purpose of this project is to develop, implement, and report on a surveillance study that will enroll and prospectively observe eligible children who are current participants in NIH/NIAID/DAIT-funded pediatric research studies and their family members. Many of these studies are focused on populations of children with asthma or other atopic conditions. The primary objective of this study will be to determine the incidence of SARS-CoV-2 infection (detection of virus in nasal secretions and stool and antibodies to the virus in blood) over time in children and their household contacts (caregivers and siblings).", "keywords": [ "2019-nCoV", "Adult", "Affect", "Agreement", "Antibodies", "Asthma", "Blood", "COVID-19", "Caregivers", "Child", "Clinic", "Clinical", "Collection", "Communicable Diseases", "Communities", "Data", "Data Collection", "Data Reporting", "Databases", "Enrollment", "Ensure", "Event", "Exposure to", "Family member", "Feces", "Fee-for-Service Plans", "Funding", "Household", "Human", "Incidence", "Infection", "Laboratories", "Logistics", "Lung diseases", "Methods", "Monitor", "National Institute of Allergy and Infectious Disease", "Nose", "Participant", "Pediatric Research", "Pediatrics", "Performance", "Periodicity", "Population", "Principal Investigator", "Protocols documentation", "Publications", "Reporting", "Research Design", "Research Personnel", "Role", "Safety", "Science", "Services", "Siblings", "Source", "System", "Time", "United States National Institutes of Health", "Universities", "Vendor", "Virus", "Work", "data management", "data quality", "epidemiologic data", "indexing", "infection burden", "infection rate", "prospective", "research study", "rho", "sound", "surveillance study", "transmission process", "viral detection", "virology" ], "approved": true } }, { "type": "Grant", "id": "15132", "attributes": { "award_id": "2430850", "title": "PSID 2025: Continuity and Change in American Economic and Social Life", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Social, Behavioral, and Economic Sciences (SBE)", "RI Social & Behavioral Science" ], "program_reference_codes": [], "program_officials": [ { "id": 1865, "first_name": "Nancy", "last_name": "Lutz", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-01", "end_date": null, "award_amount": 10999998, "principal_investigator": { "id": 31691, "first_name": "Thomas", "last_name": "Crossley", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 2564, "first_name": "Narayan", "last_name": "Sastry", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 2565, "first_name": "Katherine", "last_name": "McGonagle", "orcid": null, "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 169, "ror": "", "name": "Regents of the University of Michigan - Ann Arbor", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true } ] }, { "id": 31690, "first_name": "Esther M", "last_name": "Friedman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 169, "ror": "", "name": "Regents of the University of Michigan - Ann Arbor", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "The Panel Study of Income Dynamics (PSID) is a cornerstone of data infrastructure for social science research in the United States. The study has used a series of surveys to gather information on US families since 1968. Children and grandchildren from the original PSID families now participate as well; the result is data that follows families through several generations. The long timespan allows scientific investigation of questions about how people and families grow and change over time. This includes the study of economic outcomes such as employment, income, and wealth, research on how early life experiences affect employment and health in adulthood, research on how U.S. families cope with the needs of aging family members, and work that examines how key economic variables like consumption and employment are affected by broader businesses cycles and unanticipated events. The research team will collect one new wave of data. The new wave will include measurements of the longer run effect of the COVID-19 pandemic on PSID families. This includes measurements of the direct health impacts of the disease, the effects of disruptions to employment and education, and whether family members were helped by government efforts to reduce the burden of the pandemic. The PIs also plan new measurements of participation in short term ‘gig economy’ jobs, will expand valuable administrative data linkages, and will continue their current effort to expand web-based administration of the PSID questionnaire. The project promotes the national interest by maintaining U.S. leadership in science, by making data available to a broad community of researchers interested in understanding American families, and by providing necessary data to evaluate the long-term impacts of past policy decisions at the federal, state, and local levels of government.<br/><br/>The PSID is the world's longest running household panel survey. Through its long-term measures of economic and social wellbeing, the study allows researchers and policy analysts to investigate the dynamism inherent in social and behavioral process. The long panel, genealogical design, and broad content provide scientists a unique and powerful opportunity to study change within the same family over decades. Collecting additional waves of data from the PSID families contributes to scientific understanding of the dynamics of economic and social behavior. The extended time series of data supports new and systematic investigation of a myriad of questions in the full range of scientific disciplines that study how humans grow and change over the life cycle. This includes the study of economic outcomes (for example, the changes that occur across business cycles and changes in response to increased international economic competition), the study of intergenerational transmission of wealth and income, and the study of how income and health in adulthood and old age depend on early-life experiences. Consistent measures over time are important for accurately estimating the dynamics of these behaviors. Gathering data from the same families over many years improves the precision of the measurement as multiple measures are collected within the same families as well as from multiple families over a period of decades. The investigators will carry out numerous innovations and enhancements while maintaining core data collection for comparability. The PSID creates broader impacts in many ways. It is used by an interdisciplinary community and is increasingly important in health research. The data archive is used to inform public policy; at least nine federal agencies use PSID data. The PSID is also an important resource for teaching and learning. The data are free and publicly available. They are widely used by graduate and undergraduate students. The award funds web-based outreach activities that will make the PSID an even more valuable tool for teaching and learning.<br/><br/>This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9011", "attributes": { "award_id": "272201600013C-P00018-9999-16", "title": "MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESEARCH REPOSITORY (MID BRR) - SARS-CoV-2 THERAPEUTICS RESEARCH RELATED ACTIVITIES", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-03-04", "end_date": "2020-05-04", "award_amount": 11000208, "principal_investigator": { "id": 24837, "first_name": "TIMOTHY", "last_name": "STEDMAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1788, "ror": "https://ror.org/03thhhv76", "name": "American Type Culture Collection", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1788, "ror": "https://ror.org/03thhhv76", "name": "American Type Culture Collection", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true }, "abstract": "This contract provides unique and quality-assured infectious reagents and resources to the scientific community for use in basic research and product development. The scope of this contract includes the acquisition, authentication, production, preservation, storage, and distribution of research and reference reagents to the research community. These reagents span the pathogens in the Division of Microbiology and Infectious Diseases portfolio, and include the National Institutes of Allergy and Infectious Disease (NIAID) Category A, B and C Priority Pathogens and emerging infectious diseases.", "keywords": [ "2019-nCoV", "Basic Science", "COVID-19", "COVID-19 therapeutics", "Categories", "Communicable Diseases", "Communities", "Contracts", "Emerging Communicable Diseases", "Microbiology", "National Institute of Allergy and Infectious Disease", "Production", "Reagent", "Research", "Resources", "Therapeutic Human Experimentation", "biological research", "pathogen", "preservation", "priority pathogen", "product development", "repository", "research and development" ], "approved": true } }, { "type": "Grant", "id": "6138", "attributes": { "award_id": "3OT2HL156812-01S9", "title": "ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Neurological Disorders and Stroke (NINDS)" ], "program_reference_codes": [], "program_officials": [ { "id": 20861, "first_name": "ANTONELLO", "last_name": "PUNTURIERI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-06-15", "end_date": "2022-05-31", "award_amount": 11150020, "principal_investigator": { "id": 20862, "first_name": "Sonia M", "last_name": "Thomas", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 809, "ror": "", "name": "RESEARCH TRIANGLE INSTITUTE", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": null, "keywords": [], "approved": true } }, { "type": "Grant", "id": "9125", "attributes": { "award_id": "3UM1AI148685-01S2", "title": "COVID-19 Supplement #3 Moderna Trial", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 22843, "first_name": "RANJODH SUNNY", "last_name": "Gill", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-07-22", "end_date": "2022-11-30", "award_amount": 11154495, "principal_investigator": { "id": 10660, "first_name": "Daniel F.", "last_name": "Hoft", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 734, "ror": "https://ror.org/01p7jjy08", "name": "Saint Louis University", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 734, "ror": "https://ror.org/01p7jjy08", "name": "Saint Louis University", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "Saint Louis University (SLU) seeks to expand its service to the Vaccine and Treatment Evaluation Unit (VTEU) network providing resources and expertise to help the network achieve its objectives of evaluating vaccines, preventive biologics, therapeutics and diagnostics for infectious diseases. Dr. Daniel Hoft, SLU VTEU PI, also serves as Co-PI for a VTEU Leadership Group (LG) application supported by all current VTEUs; however, regardless of who leads the LG, SLU will provide full support to promote outstanding VTEU research. Outstanding infrastructure for phase I-IV vaccine & therapeutic trials against priority pathogens: SLU has served as a VTEU for 29 years, conducted hundreds of phase I-IV trials in healthy and special populations of all ages, and can provide unique knowledge and extensive infrastructure to support VTEU network goals. Diverse knowledge scientific skills for trial design priority areas: SLU investigators include experts in vaccinology, immunology, seasonal and pandemic influenza, tuberculosis, biodefense, urgent/emergent pandemic trials, liver/enteric diseases, sexually transmitted infections, malaria/neglected tropical diseases, epidemiology and arboviral diseases. We also provide state-of-the art multi-platform omics core expertise. Urgent national preparedness trials: SLU has led urgent trials of vaccines against potential bioweapons (smallpox, anthrax, plague and tularemia), and emergent diseases (2009 H1N1 pandemic flu, avian H5 and H7 flu and Zika/Yellow Fever). In addition to streamlined institutional review and contracting, SLU can contribute containment facilities for select agent work and inpatient human challenge. Controlled Human Infection Models: SLU has developed the capacity for human challenge models to study influenza, parainfluenza, vaccinia, salmonella and tuberculosis immunity. We provide a 23-bed airborne containment facility for challenge studies with wild type GMP influenza strains, and have developed an active collaboration with SGS to standardize challenge protocols and obtain influenza challenge strains. Expertise in First-in-Human, investigator-initiated and pharmacokinetic/pharmacodynamic studies: SLU has completed dozens of first-in-human and investigator-initiated trials of vaccines against influenza, tuberculosis, HCV, enteric pathogens, potential bioweapons and emerging flaviviruses. Experimental biology studies of mucosal and systemic immunity with human samples of blood, tissue and mucosal samples have identified biomarkers and targets for iterative influenza and tuberculosis vaccine development. Sexually transmitted infection (STI) expertise: SLU's 10 years in the HIV Vaccine Trials Network provided SLU with expertise in STI. SLU also led a 44-site herpes vaccine efficacy trial (Herpevac), and two of the highest enrolling Herpevac sites have agreed to serve as Protocol-Specific Sites to expand our STI expertise. SLU ID follows ~450 HIV patients and closely collaborates with several molecular virologists. SLU looks forward to providing its expertise and capacities to meet the new ID challenges of the future.", "keywords": [ "Adenovirus Vector", "Adjuvant", "Adult", "Age", "Anthrax disease", "Arbovirus Infections", "Area", "Attenuated", "BCG Vaccine", "Beds", "Biological Markers", "Biological Response Modifier Therapy", "Biology", "Birds", "Blood", "Blood specimen", "COVID-19", "Childhood", "Clinic", "Clinical", "Clinical Research", "Clinical Trials Design", "Collaborations", "Communicable Diseases", "Containment", "Contracts", "Dengue Fever", "Devices", "Diagnostic", "Disease", "Disease Outbreaks", "Doctor of Philosophy", "Elderly", "Enrollment", "Ensure", "Enteral", "Epidemiology", "Evaluation", "Evolution", "Faculty", "Flavivirus", "Foundations", "Future", "Goals", "HIV", "HIV Vaccine Trials Network", "Hepatitis", "Hepatitis C virus", "Human", "Immunity", "Immunology", "Infection", "Influenza", "Influenza A Virus H1N1 Subtype", "Infrastructure", "Inpatients", "Institutional Review Boards", "International", "Knowledge", "Laboratories", "Leadership", "Liver", "Malaria", "Microbiology", "Modeling", "Molecular", "Molecular Biology", "Molecular Immunology", "Mucous Membrane", "Mycobacterium bovis", "National Institute of Allergy and Infectious Disease", "Norovirus", "Nurses", "Parainfluenza", "Parasitic Diseases", "Patients", "Pediatrics", "Pharmacists", "Phase", "Phase II/III Trial", "Plague", "Prevention", "Preventive", "Procedures", "Process", "Protocols documentation", "Quarantine", "Readiness", "Recombinants", "Reporting", "Research", "Research Personnel", "Resources", "Safety", "Saints", "Salmonella", "Sampling", "Scientist", "Services", "Sexually Transmitted Diseases", "Simplexvirus", "Site", "Smallpox", "Specialist", "Standardization", "Study models", "Subunit Vaccines", "Therapeutic Trials", "Tissues", "Translational Research", "Tuberculosis", "Tuberculosis Vaccines", "Tularemia", "United States National Institutes of Health", "Universities", "Utah", "Vaccines", "Vaccinia", "Viral", "Work", "Yellow Fever", "Yellow Fever Vaccine", "ZIKA", "base", "biodefense", "bioweapon", "co-infection", "design", "disorder control", "disorder prevention", "efficacy trial", "enteric pathogen", "experience", "first-in-human", "flu", "high risk", "immunogenicity", "immunosuppressed", "industry partner", "influenza virus vaccine", "investigator-initiated trial", "medical schools", "named group", "neglected tropical diseases", "novel", "novel marker", "pandemic disease", "pandemic influenza", "pathogen", "pathogenic bacteria", "pathogenic v" ], "approved": true } }, { "type": "Grant", "id": "10645", "attributes": { "award_id": "75N93022C00055-0-9999-1", "title": "ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-19", "end_date": "2026-09-18", "award_amount": 11248167, "principal_investigator": { "id": 26702, "first_name": "KEVIN", "last_name": "SAUNDERS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "To support the advanced development of candidate products for use following the intentional release of or in response to naturally occurring outbreaks of infectious diseases, including emerging infectious diseases. This contract may support formulation and manufacture of the individual vaccine components, as well as stability testing, nonclinical immunogenicity and efficacy testing in animal models, IND enabling GLP toxicology, submission of an IND and clinical safety and efficacy evaluation.", "keywords": [ "Advanced Development", "Animal Model", "COVID-19 vaccine", "Clinical", "Communicable Diseases", "Contracts", "Disease Outbreaks", "Emerging Communicable Diseases", "Formulation", "Individual", "SARS coronavirus", "Safety", "Toxicology", "Vaccines", "efficacy evaluation", "efficacy testing", "immunogenicity", "novel coronavirus", "pandemic disease", "response", "stability testing", "vaccine development" ], "approved": true } }, { "type": "Grant", "id": "8196", "attributes": { "award_id": "75N92021P00116-0-0-1", "title": "THIS IS A CONTRACT AWARD FOR VENTUREWELL TO PROVIDE SUPPORT FOR TECHNICAL ASSESSMENTS AND PROJECT MANAGEMENT FOR THE NIBIB RAPID ACCELERATION OF DIAGN", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-04-01", "end_date": "2021-12-31", "award_amount": 11288096, "principal_investigator": { "id": 23973, "first_name": "MARK", "last_name": "MARINO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1670, "ror": "https://ror.org/00mgk5c15", "name": "VentureWell", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1670, "ror": "https://ror.org/00mgk5c15", "name": "VentureWell", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The National Institute of Biomedical Imaging and Bioengineering (NIBIB) has an open solicitation for proposals to provide up to $500 million across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American.", "keywords": [ "American", "Award", "COVID-19", "COVID-19 detection", "COVID-19 diagnostic", "COVID-19 testing", "Centers for Disease Control and Prevention (U.S.)", "Clinical", "Contracts", "Department of Defense", "Development", "Device Designs", "Diagnostic tests", "Ensure", "Exhalation", "Funding", "Goals", "Home", "Improve Access", "Laboratories", "Life Cycle Stages", "Modification", "National Institute of Biomedical Imaging and Bioengineering", "Patients", "Performance", "Point of Care Technology", "Privatization", "Program Development", "RADx", "Readiness", "Research", "Saliva", "Sampling", "Seasons", "Sensitivity and Specificity", "Speed", "Structure", "Technology", "Test Result", "Testing", "Time", "TimeLine", "United States National Institutes of Health", "Validation", "Virus", "base", "commercialization", "cost", "design", "detection limit", "flu", "handheld mobile device", "home test", "improved", "innovation", "meetings", "novel", "point of care", "product development", "programs", "scale up", "technology development", "user-friendly" ], "approved": true } } ], "meta": { "pagination": { "page": 1385, "pages": 1397, "count": 13961 } } }